The results of two human clinical trials into a stem cell therapy that can reverse symptoms of age-associated frailty have been published, and the indications are that this landmark treatment is both safe and strikingly effective in tackling key factors in aging. Mesenchymal stem cells (MSCs) are a particular type of adult stem cell generating a great deal of interest in the world of science. MSCs are currently being trailed as treatment for no less than a dozen different types of pathological conditions from cancer to heart disease.
There needs to be two larger randomized studies prior to FDA approval, but both studies led to the following results:
In the first trial 15 frail patients received a single MSC infusion collected from bone marrow donors aged between 20 and 45 years old. Six months later all patients demonstrated improved fitness outcomes, tumor necrosis factor levels and overall quality of life.
The second trial was a randomized, double blind study with placebo group. Again no adverse affects were reported and physical improvements were noted by the researchers as "remarkable".
Joshua M. Hare, Director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine said and one of the scientists who worked on the study said:
"With the aging of the population, stem cells hold great promise to treat aging-related disability and frailty, improving physical capacity and quality of life."